ArticleAnnals of neurology2021
Intrathecal Immunoglobulin M Synthesis is an Independent Biomarker for Higher Disease Activity and Severity in Multiple Sclerosis.
Abstract read
In one paragraph
Article in Annals of neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Multiplex Detection of Immunoglobulins Uncovers Intrathecal IgA Elevation in Multiple Sclerosis.Cells · 2026Article
- Emerging CSF and Serum Biomarkers in Multiple Sclerosis: Cytokines, MOG, GFAP, and Beyond.Neurology(R) neuroimmunology & neuroinflammation · 2026Article
- Intrathecal Kappa Free Light Chains in Relation to IgM Synthesis and MRZH Reaction in a Mixed Neurological Cohort.Journal of neurochemistry · 2026Article
- The Kappa Free Light Chains Index and Central Vein Sign: Two New Biomarkers for Multiple Sclerosis Diagnosis.Neurology and therapy · 2025Review
- Intrathecal Immunoglobulin A Synthesis in Multiple Sclerosis: From Biological Aspects to Clinical Relevance.Biomolecules · 2025Review
- Elevated Kappa Index in the Absence of Cerebrospinal Fluid IgG Oligoclonal Bands: Contribution of Intrathecal IgM and IgA Synthesis.Biomolecules · 2025Article
- Spinal cord lesions in relapsing-remitting multiple sclerosis: Prognostic value of intrathecal production of immunoglobulins.PloS one · 2025Article
- Intrathecal IgG and IgM synthesis correlates with neurodegeneration markers and corresponds to meningeal B cell presence in MS.Scientific reports · 2024Article
- Complement Activation Is Associated With Disease Severity in Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2024Article
- Cell-binding IgM in CSF is distinctive of multiple sclerosis and targets the iron transporter SCARA5.Brain : a journal of neurology · 2024Article
- Plasma Lipidomic Profiling Using Mass Spectrometry for Multiple Sclerosis Diagnosis and Disease Activity Stratification (LipidMS).International journal of molecular sciences · 2024Article
- Cerebrospinal fluid-related tissue damage in multiple sclerosis patients with iron rim lesions.Multiple sclerosis (Houndmills, Basingstoke, England) · 2023Article
- High levels of kappa free light chain synthesis predict cognitive decline in relapsing-remitting multiple sclerosis.Frontiers in immunology · 2023Article
- Advances in brain barriers and brain fluids research in 2021: great progress in a time of adversity.Fluids and barriers of the CNS · 2022Article
- Intrathecal IgM Synthesis Is Associated with Spinal Cord Manifestation and Neuronal Injury in Early MS.Annals of neurology · 2022Article
- Application of the "risk of ambulatory disability" (RoAD) score in a "real-world" single-center multiple sclerosis cohort.CNS neuroscience & therapeutics · 2022Article
- Biological Markers in Early Multiple Sclerosis: the Paved Way for Radiologically Isolated Syndrome.Frontiers in immunology · 2022Review
- High Levels of Cerebrospinal Fluid Kappa Free Light Chains Relate to IgM Intrathecal Synthesis and Might Have Prognostic Implications in Relapsing Multiple Sclerosis.Frontiers in immunology · 2022Observational
- Increased intrathecal neurofilament light and immunoglobulin M predict severe disability in relapsing-remitting multiple sclerosis.Frontiers in immunology · 2022Observational
- Cerebrospinal Fluid IgM and Oligoclonal IgG Bands in Multiple Sclerosis: A Meta-Analysis of Prevalence and Prognosis.Brain sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
39 authors.
Johanna OechteringNeurology Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, Basel, Switzerland.
Sabine SchaedelinClinical Trial Unit, Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.
Pascal BenkertClinical Trial Unit, Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.
Stefanie MüllerDepartment of Neurology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
Lutz AchtnichtsDepartment of Neurology, Cantonal Hospital Aarau, Aarau, Switzerland.
Jochen VehoffDepartment of Neurology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
Giulio DisantoNeurocentre of Southern Switzerland, Multiple Sclerosis Centre, Ospedale Civico, Lugano, Switzerland.
Oliver FindlingDepartment of Neurology, Cantonal Hospital Aarau, Aarau, Switzerland.
Bettina Fischer-BarnicolNeurology Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, Basel, Switzerland.
Annette OrlethNeurology Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, Basel, Switzerland.
Andrew ChanDepartment of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.
Caroline PotDivision of Neurology, Department of Clinical Neurosciences, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.
Muhamed BarakovicNeurology Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, Basel, Switzerland.
Reza RahmanzadehNeurology Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, Basel, Switzerland.
Riccardo GalbuseraNeurology Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, Basel, Switzerland.
Ingmar HeijnenDivision of Medical Immunology, Laboratory Medicine, University Hospital Basel, Basel, Switzerland.
Patrice H LaliveDepartment of Clinical Neurosciences, Division of Neurology, Geneva University Hospital, Geneva, Switzerland.
Jens WuerfelMedical Image Analysis Center (MIAC) and Department of Biomedical Engineering, University Basel, Basel, Switzerland.
Suvitha SubramaniamClinical Trial Unit, Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.
Stefanie AeschbacherCardiovascular Research Institute Basel, University Hospital Basel, Basel, Switzerland.
David ConenPopulation Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
Yvonne NaegelinNeurology Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, Basel, Switzerland.ORCID 0000-0002-1315-4100
Aleksandra MaceskiNeurology Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, Basel, Switzerland.
Stephanie MeierNeurology Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, Basel, Switzerland.
Klaus BergerInstitute of Epidemiology and Social Medicine, University of Münster, Münster, Germany.
Heinz WiendlDepartment of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.
Therese LinckeDivision of Neuroradiology, Department of Radiology and Nuclear Medicine, University Hospital Basel, University of Basel, Basel, Switzerland.
Johanna LiebDivision of Neuroradiology, Department of Radiology and Nuclear Medicine, University Hospital Basel, University of Basel, Basel, Switzerland.
Özgür YaldizliNeurology Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, Basel, Switzerland.
Tim SinneckerNeurology Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, Basel, Switzerland.
Tobias DerfussNeurology Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, Basel, Switzerland.
Axel RegeniterMedica Laboratory, Zürich, Switzerland.
Chiara ZeccaNeurocentre of Southern Switzerland, Multiple Sclerosis Centre, Ospedale Civico, Lugano, Switzerland.
Claudio GobbiNeurology Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, Basel, Switzerland.
Ludwig KapposNeurology Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, Basel, Switzerland.
Cristina GranzieraNeurology Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, Basel, Switzerland.
David LeppertNeurology Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, Basel, Switzerland.
Jens KuhleNeurology Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, Basel, Switzerland.ORCID 0000-0002-6963-8892
Swiss Multiple Sclerosis Cohort Study
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWe aimed to determine in relapsing multiple sclerosis (MS) whether intrathecal synthesis of immunoglobulin (Ig) M and IgG is associated with outcomes reflecting inflammatory activity and chronic worsening.
methodsWe compared cerebrospinal fluid analysis, clinical and magnetic resonance imaging data, and serum neurofilament light chain (sNfL) levels at baseline and follow-up in 530 patients with relapsing MS. Patients were categorized by the presence of oligoclonal IgG bands (OCGB) and intrathecal synthesis of IgG and IgM (intrathecal fraction [IF]: IgG
resultsBy categorical analysis, in patients with IgM
interpretationThis large study supports the value of intrathecal IgM synthesis as an independent biomarker of disease activity and severity in relapsing MS. ANN NEUROL 2021;90:477-489.
Indexed as
Disease ProgressionSeverity of Illness IndexAdultBiomarkersCohort StudiesFemaleFollow-Up StudiesHumansImmunoglobulin MMagnetic Resonance ImagingMaleMiddle AgedMultiple SclerosisNeurofilament ProteinsSpinal PunctureYoung AdultBiomarkersImmunoglobulin Mneurofilament protein LNeurofilament Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.